Special Issue "HDAC Inhibitors"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 July 2011)
Prof. Dr. H. Miles Prince
Centre for Blood Cell Therapies, Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Locked Bag 1, A\'Beckett St Melbourne 8006, Victoria, Australia
Interests: blood clotting; bleeding disorders; transfusion medics; myeloma therapy (clinical and pre-clinial)and biology; cutaneous T cell lymphoma (clinical); immunotherapy; epigenetics
Histone deacetylase inhibitors are clearly effective therapeutic tools in the treatment of cancers, particularly haematological malignancies. The purpose of this special issue is to provide the reader with a focused review of on the current place of HDACi as a therapy, particularly in blood cancers. We hope to provide a broad overview of the rationale behind their use, with specific papers focusing on diseases where they clearly have biological effects - NHL, Hodgkin disease, myeloid malignancies. Finally we hope to have two seperate papers examining mechanisms of resistance and common toxicities.
I hope you will be able to contribute to what I see will be a valuable compendium of insightful reviews in this very topical subject.
Prof. Dr. H. Miles Prince
- histone deacetylase
- novel therapies
- transcription factors
Review: Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
Pharmaceuticals 2010, 3(8), 2441-2469; doi:10.3390/ph3082441
Received: 16 July 2010; in revised form: 30 July 2010 / Accepted: 2 August 2010 / Published: 4 August 2010| Cited by 16 | PDF Full-text (413 KB) | HTML Full-text | XML Full-text
Pharmaceuticals 2010, 3(8), 2674-2688; doi:10.3390/ph3082674
Received: 23 July 2010; in revised form: 12 August 2010 / Accepted: 13 August 2010 / Published: 17 August 2010| Cited by 1 | PDF Full-text (163 KB) | HTML Full-text | XML Full-text
Pharmaceuticals 2010, 3(9), 2751-2767; doi:10.3390/ph3092751
Received: 23 June 2010; in revised form: 18 August 2010 / Accepted: 19 August 2010 / Published: 26 August 2010| Cited by 17 | PDF Full-text (130 KB) | HTML Full-text | XML Full-text
Article: Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration
Pharmaceuticals 2011, 4(8), 1183-1195; doi:10.3390/ph4081183
Received: 25 July 2011; in revised form: 11 August 2011 / Accepted: 15 August 2011 / Published: 22 August 2011| Cited by 2 | PDF Full-text (571 KB) | HTML Full-text | XML Full-text
Article: Improved Histone Deacetylase Inhibitors as Therapeutics for the Neurodegenerative Disease Friedreich’s Ataxia: A New Synthetic Route
Pharmaceuticals 2011, 4(12), 1578-1590; doi:10.3390/ph4121578
Received: 18 October 2011; in revised form: 30 November 2011 / Accepted: 30 November 2011 / Published: 14 December 2011| Cited by 2 | PDF Full-text (368 KB) | HTML Full-text | XML Full-text
Last update: 4 March 2014